Every material Form 8-K MEDICINOVA INC has filed with the SEC since August 19, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
MediciNova amended its office lease, extending the end date from January 31, 2027 to April 30, 2030, and agreed to rent increases starting February 1, 2027. The filing is an administrative lease change with no revenue, earnings, or guidance effect, though it commits the company to a longer occupancy period at higher rent.
Lease end date extended from January 31, 2027 to April 30, 2030, unless terminated earlier under the lease terms
Rent increases take effect February 1, 2027; the filing does not state amounts
Amendment dated September 23, 2026, with Newport Gateway Office LLC; original lease dated July 20, 2021 with Irvine Company LLC
Full amendment expected to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026
MediciNova notified Yorkville on August 31, 2026 that it is terminating the Standby Equity Purchase Agreement dated July 30, 2025, with termination effective September 8, 2026. Under the agreement, the company could have sold up to $30.0 million of its common stock, but it sold only 175,000 shares for $0.2 million, and no borrowings or fees are outstanding.
Standby Equity Purchase Agreement with Yorkville dated July 30, 2025; termination notice delivered August 31, 2026, effective September 8, 2026
Agreement allowed sales of up to $30.0 million of common stock; company sold 175,000 shares at $1.39 to $1.40 per share for $0.2 million
No outstanding borrowings, advance notices or shares to be issued, and no termination fees owed by either party
On August 17, 2026, MediciNova signed new executive employment agreements with CEO Yuichi Iwaki and Chief Medical Officer Kazuko Matsuda, replacing their prior employment and severance arrangements. The agreements set base salaries, bonus targets and enhanced change-in-control severance, which matters to shareholders because it defines potential future costs tied to these executives.
Dr. Iwaki's base salary is $690,246 with a target bonus of 55% of salary; Dr. Matsuda's base salary is $540,143 with a target bonus of 40%.
Following a change in control, Dr. Iwaki would receive 24 months of base salary plus 24 months of target bonus; Dr. Matsuda would receive 18 months of each.
Without a change in control, involuntary termination pays 12 months of base salary for both executives.
The full agreements will be filed with the Form 10-Q for the quarter ended September 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MEDICINOVA INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →